Shots:

• Lilly has expanded its ongoing BLAZE-4 trial to assess the administration of bamlanivimab (700mg) with VIR-7831 (500mg) for symptomatic COVID-19 in the outpatient setting. These are two neutralizing Abs that bind to different epitopes of the SARS-CoV-2 spike protein
• The companies reported the first patient has been dosed in the expanded study
• Bamlanivimab is authorized for emergency use in the US for mild-to-mod. COVID-19 in high-risk patients. VIR-7831 is being evaluated in the global P-II/III COMET-ICE trial for the early treatment of COVID-19 in adults at high risk of hospitalization

 ­ Ref: GSk | Image: GSk